Institution: Sumitomo Dainippon Pharma
Headquarters: Tokyo, Japan
Allocation to alternatives: 5.24%
Sumitomo Dainippon Pharma has announced its private equity commitment to MPM Oncology Innovations Fund for an undisclosed amount. By committing to the fund, the firm can support early-stage companies in the healthcare, biotech and life science sectors.
As illustrated below, Sumitomo Dainippon Pharma has made five private equity fund commitments which focus on healthcare, biotech and life science sectors.
Platinum subscribers may click here for the investor’s full profile, including key contacts, allocation strategy and fund investments.